Increased serum levels of anti-angiogenic factors soluble fms-like tyrosine kinase and soluble endoglin in sickle cell disease

Acta Haematologica

Volumn 120, Issue 3, 2009, Pages 130-133

  Landburg, P P ^a,b   Elsenga, H ^a   Schnog, J B ^a,b   Duits, A J ^a  

^a Red Cross Blood Bank Foundation   (Netherlands Antilles)

^b St Elisabeth Hospital Willemstad   (Netherlands Antilles)

Author keywords

Angiogenesis; Endoglin; fms like tyrosine kinase; Placenta like growth factor; sEng; sFlt 1; Sickle cell disease; Vascular endothelial growth factor

Indexed keywords

ENDOGLIN; FIBROBLAST GROWTH FACTOR RECEPTOR 1; PLACENTAL GROWTH FACTOR; TRANSFORMING GROWTH FACTOR BETA1; VASCULOTROPIN;

ANGIOGENESIS; ARTICLE; BLOOD VESSEL OCCLUSION; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; PATIENT MONITORING; PRIORITY JOURNAL; PROTEIN FUNCTION; REGULATORY MECHANISM; RISK ASSESSMENT; SICKLE CELL ANEMIA; SIGNAL TRANSDUCTION;

ANEMIA, SICKLE CELL; ANGIOGENESIS INHIBITORS; ANTIGENS, CD; FEMALE; HUMANS; MALE; NEOVASCULARIZATION, PATHOLOGIC; RECEPTORS, CELL SURFACE; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA1; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 56749103265     PISSN: 00015792     EISSN: None     Source Type: Journal    
DOI: 10.1159/000178143     Document Type: Article

References (19)

1. Stuart MJ, Nagel RL: Sickle-cell disease. Lancet 2004;364:1343-1360.
2. Carmeliet P: Angiogenesis in health and disease. Nat Med 2003;9:653-660.
3. Duits AJ, Rodriguez T, Schnog JJ: Serum levels of angiogenic factors indicate a pro-angiogenic state in adults with sickle cell disease. Br J Haematol 2006;134:116-119.
4. Levine RJ, Lam C, Qian C, Yu KF, Maynard SE, Sachs BP, Sibai BM, Epstein FH, Romero R, Thadhani R, Karumanchi SA: Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med 2006;355:992-1005.
5. Ashley-Koch AE, Elliott L, Kail ME, De Castro LM, Jonassaint J, Jackson TL, Price J, Ataga KI, Levesque MC, Weinberg JB, Orringer EP, Collins A, Vance JM, Telen MJ: Identification of genetic polymorphisms associated with risk for pulmonary hypertension in sickle cell disease. Blood 2008;111:5721-5726.
6. Nolan VG, Adewoye A, Baldwin C, Wang L, Ma Q, Wyszynski DF, Farrell JJ, Sebastiani P, Farrer LA, Steinberg MH: Sickle cell leg ulcers: associations with haemolysis and SNPs in Klotho, TEK and genes of the TGF-beta/ BMP pathway. Br J Haematol 2006;133:570-578.
7. Sebastiani P, Ramoni MF, Nolan V, Baldwin CT, Steinberg MH: Genetic dissection and prognostic modeling of overt stroke in sickle cell anemia. Nat Genet 2005;37:435-440.
8. Nolan VG, Baldwin C, Ma Q, Wyszynski DF, Amirault Y, Farrell JJ, Bisbee A, Embury SH, Farrer LA, Steinberg MH: Association of single nucleotide polymorphisms in klotho with priapism in sickle cell anaemia. Br J Haematol 2005;128:266-272.
9. Nevo O, Soleymanlou N, Wu Y, Xu J, Kingdom J, Many A, Zamudio S, Caniggia I: Increased expression of sFlt-1 in in vivo and in vitro models of human placental hypoxia is mediated by HIF-1. Am J Physiol Regul Integr Comp Physiol 2006;291:R1085-R1093.
10. Kerbel RS: Tumor angiogenesis. N Engl J Med 2008;358:2039-2049.
11. Perelman N, Selvaraj SK, Batra S, Luck LR, Erdreich-Epstein A, Coates TD, Kalra VK, Malik P: Placenta growth factor activates monocytes and correlates with sickle cell disease severity. Blood 2003;102:1506-1514.
12. Venkatesha S, Toporsian M, Lam C, Hanai J, Mammoto T, Kim YM, Bdolah Y, Lim KH, Yuan HT, Libermann TA, Stillman IE, Roberts D, D'Amore PA, Epstein FH, Sellke FW, Romero R, Sukhatme VP, Letarte M, Karumanchi SA: Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med 2006;12:642-649.
13. Li C, Hampson IN, Hampson L, Kumar P, Bernabeu C, Kumar S: CD105 antagonizes the inhibitory signaling of transforming growth factor beta1 on human vascular endothelial cells. FASEB J 2000;14:55-64.
14. Reiter CD, Gladwin MT: An emerging role for nitric oxide in sickle cell disease vascular homeostasis and therapy. Curr Opin Hematol 2003;10:99-107.
15. Sanchez-Elsner T, Botella LM, Velasco B, Corbi A, Attisano L, Bernabeu C: Synergistic cooperation between hypoxia and transforming growth factor-beta pathways on human vascular endothelial growth factor gene expression. J Biol Chem 2001;276:38527-38535.
16. Sanchez-Elsner T, Botella LM, Velasco B, Langa C, Bernabeu C: Endoglin expression is regulated by transcriptional cooperation between the hypoxia and transforming growth factor-beta pathways. J Biol Chem 2002;277:43799-43808.
17. Schnog JJ, Lard LR, Rojer RA, Van der Dijs FP, Muskiet FA, Duits AJ: New concepts in assessing sickle cell disease severity. Am J Hematol 1998;58:61-66.
18. van Beers EJ, van Tuijn CF, Mac Gillavry MR, van der Giessen A, Schnog JJ, Biemond BJ, CURAMA Study Group: Sickle cell disease-related organ damage occurs irrespective of pain rate: implications for clinical practice. Haematologica 2008;93:757-760.
19. Mohan JS, Lip PL, Blann AD, Bareford D, Lip GY: The angiopoietin/Tie-2 system in proliferative sickle retinopathy: relation to vascular endothelial growth factor, its soluble receptor Flt-1 and von Willebrand factor, and to the effects of laser treatment. Br J Ophthalmol 2005;89:815-819.